BOSTON and ROLLE, Switzerland, June 26,
2023 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq:
SOPH), a cloud-native software company in the healthcare space and
a leader in data-driven medicine, is pleased to announce that its
Annual General Shareholders Meeting (the "AGM") was held at
the Company's new headquarters, La Piece 12, 1180 Rolle VD,
Switzerland, earlier today at
14:00 CEST (8:00 a.m. EDT).
The Company's shareholders approved each agenda item presented
at the AGM. The AGM minutes and detailed voting results by agenda
item, along with the 2022 ESG Impact Summary, will be published on
the Company's website in the investor section. They will also be
filed with the U.S. Securities and Exchange Commission on Form
6-K.
Additionally, the Company would like to welcome the newly
appointed director Lila Tretikov to its Board of Directors.
Tretikov will be a strong addition to the Board of Directors, as
she is a tremendous leader in the artificial intelligence (AI) and
technology worlds. The Company looks forward to Tretikov's future
contributions.
The Company would also like to thank all shareholders
represented for their votes and for their valued commitment and
support.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook,
and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-publishes-results-of-2023-annual-general-meeting-301863322.html
SOURCE SOPHiA GENETICS